10 completed, 5 unknown, 4 recruiting, 1 active not recruiting. 22 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Completed 10, Unknown 5, Recruiting 4, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1 |
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
Follow Nicotinamide: new trials by email Literature Review of Nicotinamide trials Research Report on Nicotinamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial) Nicotinamide, Standard Glaucoma Therapy - Glaucoma, Open-angle, Primary Open Angle Glaucoma (POAG) | Phase 2 | Not yet recruiting | University of Chicago | 96 | 2027-06-01 | 2026-10-13 |
| Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Antiretrovirals Maraviroc, Dolutegravir, Dendritic Cell Vaccine - Hiv, HIV I Infection | Phase 2 | Recruiting | Federal University of São Paulo | 70 | 2026-07-15 | 2026-08-19 |
| Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients Nicotinamide Riboside, Nicotinamide, Nicotinamide Mononucleotide - Glaucoma | Phase 2 | Recruiting | Christopher Kai Shun Leung | 138 | 2025-05-19 | 2025-06-26 |
| Nicotinamide Supplementation Improves Physical Performance in Older Adults at Risk of Falls Nicotinamide, Placebo - Frailty, Fall | Phase 2 | Unknown | University of Chile | 60 | 2024-05-21 | 2024-06-20 |
| Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB) Nicotinamide, Placebo - Fatty Liver, Obesity | Phase 2 | Recruiting | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 30 | 2024-04-23 | 2025-11-18 |
| Tolerance and Efficacy Nicotinamide (Vitamin B3) in Dominant Optic Atrophy OPA1 Nicotinamide - Nicotinamide Adverse Reaction | Phase 2 / Phase 3 | Active not recruiting | University Hospital, Angers | 25 | 2024-01-23 | 2026-04-01 |
| Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia Nicotinamide, Placebo - Friedreich Ataxia | Phase 2 | Withdrawn | RWTH Aachen University | 2023-04-01 | 2024-01-24 | |
| Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers Nicotinamide, Placebo - Chronic Lymphocytic Leukemia, Non-melanoma Skin Cancer (NMSC) | Phase 2 | Recruiting | University of Utah | 86 | 2022-02-25 | 2026-11-12 |
| Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression Psilocybin, Nicotinamide - Treatment-resistant Depression | Phase 2 | Completed | Central Institute of Mental Health, Mannheim | 144 | 2021-06-10 | 2025-01-20 |
| Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients Niacinamide Oral Tablet, Antidiabetic - Non Alcoholic Fatty Liver Disease | Phase 2 | Completed | Ain Shams University | 61 | 2019-01-15 | 2020-01-22 |
| Skin Cancer Prevention With Nicotinamide in Transplant Recipients - Pilot Trial Nicotinamide, Placebo oral capsule - Non-melanoma Skin Cancer, Carcinoma, Squamous Cell | Phase 2 | Unknown | Women's College Hospital | 120 | 2018-12-03 | 2023-04-06 |
| Study of Nicotinamide in Early Onset Preeclampsia nicotinamide - Pre-Eclampsia, Pregnancy Related | Phase 2 | Completed | University of North Carolina, Chapel Hill | 23 | 2017-11-01 | 2022-09-08 |
| Early Life Interventions for Childhood Growth and Development In Tanzania Azithromycin Oral Liquid Product, Nitazoxanide Oral Suspension, Nicotinamide - Malnutrition, Stunting | Phase 2 / Phase 3 | Completed | Haydom Lutheran Hospital | 1188 | 2017-09-05 | 2021-05-10 |
| Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus nicotinamide - Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus Rash | Phase 2 | Unknown | Second Xiangya Hospital of Central South University | 40 | 2017-08-31 | 2021-02-02 |
| Nicotinamide as an Early Alzheimer's Disease Treatment Nicotinamide, Placebo Comparator - Alzheimer's Disease, Mild Cognitive Impairment | Phase 2 | Completed | University of California, Irvine | 46 | 2017-07-12 | 2023-10-17 |
| Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2) Niacinamide, Placebo - Polycystic Kidney Disease | Phase 2 | Completed | University of Kansas Medical Center | 36 | 2015-09-22 | 2019-02-11 |
| The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE Nicotinamide, Lanthanum Carbonate, Placebo (for Nicotinamide) - Chronic Kidney Disease | Phase 2 | Completed | The Cleveland Clinic | 205 | 2015-03-01 | 2021-08-02 |
| Anticancer Activity of Nicotinamide on Lung Cancer Nicotinamide - Non-Small-Cell Lung Carcinoma | Phase 2 / Phase 3 | Unknown | Il Yeong Park, Ph.D. | 110 | 2015-03-01 | 2020-01-27 |
| Effect of Nicotinamide in Friedreich's Ataxia nicotinamide - Neurodegenerative Disorders | Phase 2 | Unknown | Imperial College London | 40 | 2012-06-01 | 2017-07-02 |
| Nicotinamide in Hemodialysis Patients With Hyperphosphatemia Nicotinamide - Chronic Kidney Disease, Hemodialysis | Phase 2 | Completed | Medice Arzneimittel Pütter GmbH & Co KG | 252 | 2010-08-01 | 2012-01-18 |
Showing 20 of 22. Sign in to see all of them.
Alzheimer Disease (2) · Dementia (2) · Neurodegenerative Diseases (2) · Non-alcoholic Fatty Liver Disease (2) · Renal Insufficiency, Chronic (2) · Acquired Immunodeficiency Syndrome (1) · Anxiety Disorders (1) · Carcinoma, Basal Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Squamous Cell (1) · Cognitive Dysfunction (1) · Depression (1) · Depressive Disorder, Major (1) · Depressive Disorder, Treatment-Resistant (1) · Fatty Liver (1)
University of California, Irvine (2) · Ain Shams University (1) · Central Institute of Mental Health, Mannheim (1) · Christopher Kai Shun Leung (1) · Federal University of São Paulo (1) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) · Haydom Lutheran Hospital (1) · Il Yeong Park, Ph.D. (1) · Imperial College London (1) · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (1) · Medice Arzneimittel Pütter GmbH & Co KG (1) · RWTH Aachen University (1) · Second Xiangya Hospital of Central South University (1) · The Cleveland Clinic (1) · University Hospital, Angers (1)
United States (8) · Germany (3) · France (2) · Spain (2) · United Kingdom (2) · Austria (1) · Brazil (1) · Canada (1) · Chile (1) · China (1) · Egypt (1) · Hong Kong (1) · Italy (1) · South Korea (1) · Tanzania (1)
Alan Yu, M.B., B.Chir (1) · An-Wen Chan, MD DPhil (1) · Charles S. Grob, MD (1) · Estomih Mduma (1) · Felipe H Salech Morales, MD-PhD (1) · Il Yeong Park, PhD (1) · Jennifer J Gassman, Ph.D. (1) · John W. Kusek, PhD (1) · Joseph Kim, MD PhD (1) · Joshua Grill, Ph.D. (1) · Kim Boggess, MD (1) · Linda F Fried, MD (1) · Lindsey Fitzgerald, MD (1)
PMID 20819978, PMID 24794816, PMID 29982218, PMID 31085679, PMID 32345747, PMID 33324899, PMID 34582462, PMID 35222903, PMID 36963502, PMID 38570905, PMID 38593249, PMID 39032770, PMID 39356039, PMID 39671543, PMID 40069789, PMID 40576086, PMID 41232946, PMID 41848690, PMID 42309304
2009 (1), 2023 (1), R03HD092370 (1), R21DK104086 (1), U01DK099877 (1)